Head to Head Comparison: NantHealth (NH) & Simulations Plus (SLP)
NantHealth (NYSE: NH) and Simulations Plus (NASDAQ:SLP) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, profitability and analyst recommendations.
This is a breakdown of recent recommendations and price targets for NantHealth and Simulations Plus, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
NantHealth currently has a consensus target price of $9.25, indicating a potential upside of 230.36%. Given NantHealth’s higher probable upside, equities analysts plainly believe NantHealth is more favorable than Simulations Plus.
Simulations Plus pays an annual dividend of $0.20 per share and has a dividend yield of 1.4%. NantHealth does not pay a dividend. Simulations Plus pays out 62.5% of its earnings in the form of a dividend.
This table compares NantHealth and Simulations Plus’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares NantHealth and Simulations Plus’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|NantHealth||$98.18 million||3.48||-$116.13 million||N/A||N/A|
|Simulations Plus||$21.83 million||11.22||$9.15 million||$0.32||44.38|
Simulations Plus has higher revenue, but lower earnings than NantHealth.
Insider and Institutional Ownership
32.0% of Simulations Plus shares are owned by institutional investors. 36.9% of Simulations Plus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Simulations Plus beats NantHealth on 8 of the 12 factors compared between the two stocks.
NantHealth, Inc. is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples. The Company also offers Nant Operating System (NantOS) and NantOS applications to healthcare providers and payors, self-insured employers and biopharmaceutical companies. It offers CLINICS, an integrated solution that includes GPS Cancer, NantOS and the NantOS applications. The CLINICS solution includes System Infrastructure, Knowledge Platform, Provider Platform and Payor Platform.
About Simulations Plus
Simulations Plus, Inc. (Simulations Plus) develops and produces software for use in pharmaceutical research and for education, and provides consulting and contract research services to the pharmaceutical industry. The Company offers five software products for pharmaceutical research. ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) Predictor is a computer program that takes molecular structures as inputs and predicts over 140 different properties for them at the rate of about 200,000 compounds per hour. MedChem Designer includes a small set of ADMET Predictor property predictions, allowing the chemist to modify molecular structures. MedChem Studio is a tool for medicinal and computational chemists for both data mining and for designing new drug-like molecules. DDDPlus simulates in-vitro laboratory experiments used to measure the rate of dissolution of the drug. GastroPlus simulates the absorption, pharmacokinetics, and pharmacodynamics of drugs.
Receive News & Ratings for NantHealth Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.